Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: Design of a follow-up protocol and baseline results;Efectos secundarios del tratamiento antipsicótico en niños y adolescentes naïve o quasi-naïve: Diseño de un protocolo de seguimiento y resultados basales

Revista de Psiquiatria y Salud Mental

Volumn 5, Issue 4, 2012, Pages 217-228

  Merchán Naranjo, Jessica ^a   Tapia, Cecilia ^a   Bailón, Concha ^a   Moreno, Carmen ^a   Baeza, Inmaculada ^b   Calvo Escalona, Rosa ^b   Morer, Astrid ^b   Martínez Cantarero, Carmen ^c   Nestares, Patricia Andrés ^c   Alda, José Ángel ^d   Muñoz, Daniel ^d   Arango, Celso ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Antipsychotic; Cardiology; Extrapyramidal; Metabolic; Pediatric population

Indexed keywords

NEUROLEPTIC AGENT;

ACCOMMODATION DISORDER; ADOLESCENT; AKATHISIA; AKINESIA; ANXIETY DISORDER; ARTICLE; CHILD; CLINICAL PROTOCOL; DREAMING; DROWSINESS; DRUG INDUCED HEADACHE; EMOTIONAL DISORDER; FATIGUE; FOLLOW UP; HUMAN; HYPOKINESIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PARESTHESIA; PARKINSONISM; POLYDIPSIA; POLYURIA; SALIVATION; SEDATION; SEXUAL AROUSAL; SIDE EFFECT; SWEATING; TENSION HEADACHE;

EID: 84873096961     PISSN: 18889891     EISSN: 19894600     Source Type: Journal    
DOI: 10.1016/j.rpsm.2012.03.006     Document Type: Article

References (43)

1. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004;158:753-9.
2. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63:679-85.
3. Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21:600-20.
4. Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, et al. Efficacy and safety of secondgeneration antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011;21:621-45.
5. Fraguas D, Merchán-Naranjo J, Arango C. Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents. Rev Psiquiatr Salud Ment. 2010;3:152-67.
6. Laita P, Cifuentes A, Doll A, Llorente C, Cortés I, Parellada M, et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol. 2007;17:487-502.
7. Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005;44:548-56.
8. Arango C, Parellada M, Moreno DM. Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol. 2004;14 Suppl. 4:S471-9.
9. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66 Suppl. 7:29-40.
10. Vitiello B, Correll C, Van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19:629-35.
11. Pathak P, West D, Martin BC, Helm ME, Henderson C. Evidencebased use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61:123-9.
12. Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2008;121:1002-9.
13. Kalverdijk LJ, Tobi H, Van den Berg PB, Buiskool J, Wagenaar L, Minderaa RB, et al. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv. 2008;59:554-60.
14. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420-31.
15. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47:9-20.
16. Fraguas D, Merchán-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry. 2008;69:1166-75.
17. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet. 2009;373:4-5.
18. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res. 2008;99:13-22.
19. Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry. 2009;18:418-28.
20. Pina L, Merchán-Naranjo J, García-Amador M. C A. Metabolic side effects in antipsychotic-naïve adolescents after 12 months of treatment with second-generation antipsychotics. Schizophrenia Bulletin. 2011;37 Suppl. 1:29.
21. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119:171-9.
22. Moreno C, Merchán-Naranjo J, Álvarez M, Baeza I, Alda JA, Martínez-Cantarero C, et al. Metabolic effects of secondgeneration antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord. 2010;12:172-84.
23. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765-73.
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA; 1994.
25. Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fernández-Ramos C, Lizárraga A, et al. Curvas y tablas de crecimiento: estudios longitudinal y transversal. Bilbao: Fundación Faustino Orbegozo Eizaguirre; 2004.
26. Serra L, Aranceta J, Pérez C, Moreno B, Tojo R, Delgado A, et al. Curvas de referencia para la tipificación ponderal. En: AEPSENC-SEEDO, editor. Criterios para la prevención de la obesidad infantil y juvenil. Documento de consenso del grupo colaborativo AEP-SENC-SEEDO. Dossier de consenso. Madrid: IM&C; 2002.
27. National highblood pressure education Program working group on high blood pressure in children and adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576.
28. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67:255-62.
29. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291-303.
30. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45:13-23.
31. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
32. Cassady SL, Thaker GK, Summerfelt A, Tamminga CA. The Maryland Psychiatric Research Center scale and the characterization of involuntary movements. Psychiatry Res. 1997;70: 21-37.
33. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull. 2002;28:105-9.
34. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem. 2004;11:313-27.
35. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68:1751-62.
36. Simon V, Van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70:1041-50.
37. Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol. 2002;12:83-91.
38. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19: 611-21.
39. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, De Hert M, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol. 2009;19: 520-32.
40. Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, et al. A comparative pilot study of secondgeneration antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol. 2008;18:317-26.
41. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771-91.
42. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12:116-41.
43. DelBello MP, Correll CU. Primum non nocere: balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder. Bipolar Disord. 2010;12:113-5.